Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6321915 | 0.94 | MAPT (0.45) | ALDH1A1POLBMAPTMAPK1GAA | |
| SCHEMBL5263394 | 0.93 | ALDH1A1 (0.39) | ALDH1A1POLBMAPTMAPK1GAA | |
| SCHEMBL4458512 | 0.92 | MALT1 (0.43) | LMNA | |
| Hydrochloric Acid SCHEMBL6313508 | 0.91 | MALT1 (0.42) | LMNA | |
| SCHEMBL7359681 | 0.89 | MALT1 (0.47) | MAPTGAA | |
| SCHEMBL6321469 | 0.85 | NAMPT (0.42) | ALDH1A1POLBMAPTGAALMNA | |
| SCHEMBL6319630 | 0.84 | ALDH1A1 (0.41) | ALDH1A1POLBMAPTMAPK1GAA | |
| Hydrochloric Acid SCHEMBL6313151 | 0.84 | NAMPT (0.41) | ALDH1A1POLBMAPTGAALMNA | |
| SCHEMBL6312734 | 0.84 | NR4A3 (0.49) | ALDH1A1POLBMAPTMAPK1GAA | |
| Hydrochloric Acid SCHEMBL6313446 | 0.84 | SLC9A1 (0.46) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216257-B1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2005-12-07 | — | — | EP | claimed |
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | claimed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | claimed |
| US-20030212104-A1 | Treatment of diabetes and diabetic complications with NHE-1 inhibitors | PFIZER INC. | 2003-11-13 | — | — | US | claimed |
| US-20030212072-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2003-11-13 | — | — | US | claimed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | claimed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | claimed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | claimed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | claimed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | claimed |
| CN-1370531-A | Combined therapy | PFIZER PRODUCT CO (US) | 2002-09-25 | — | — | CN | claimed |
| EP-1226830-A2 | Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia | Pfizer Products Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| US-6423705-B1 | FOR ISCHEMIA BY ADMINISTERING AN NHE-1 INHIBITOR AND A SECOND COMPOUND SELECTED FROM COMPLEMENT MODULATOR, METABOLIC MODULATOR, ANTIAPOPTOTIC AGENT, NITRIC OXIDE SYNTHASE-RELATED AGENT, AND AN ENZYME/PROTEIN MODULATOR | PFIZER INC. | 2002-07-23 | — | — | US | claimed |
| US-20010056095-A1 | Salts of zopolrestat | MYLARI BANAVARA L (US) | 2001-12-27 | — | — | US | claimed |
| WO-2015189236-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING CD95-MEDIATED CELL MOTILITY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-12-17 | — | — | WO | disclosed |
| US-7572910-B2 | Pyridazinone aldose reductase inhibitors | PFIZER, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-6294538-B1 | ANTIDIABETIC AGENTS AND DIABETIC NEUROPATHY, TREATMENT WITH OXIDOREDUCTASE ENZYMES | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1041068-A1 | Compounds for treating and preventing diabetic complications | Pfizer Products Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056095-A1 | Salts of zopolrestat | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 257/4885POLB 3589/4885MAPT 256/4885 |
| US-20030212104-A1 | Treatment of diabetes and diabetic complications with NHE-1 inhibitors | NHERF1, SLC5A1, SLC5A2 | ALDH1A1 1352/4885POLB 4458/4885MAPT 3477/4885 |
| US-20030055021-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | ALDH1A1 378/4885POLB 2114/4885MAPT 4649/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | ALDH1A1 25/4885POLB 4044/4885MAPT 2399/4885 |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | ALDH1A1 642/4885POLB 2803/4885MAPT 4418/4885 |
| US-20030212072-A1 | Salts of zopolrestat | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 257/4885POLB 3589/4885MAPT 256/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | ALDH1A1 25/4885POLB 4044/4885MAPT 2399/4885 |
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | ALDH1A1 1085/4885POLB 2299/4885MAPT 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.